Vericel Corporation recently issued preliminary, unaudited guidance for the fourth quarter and full year 2025, pointing to 23% quarterly revenue and MACI sales growth and approximately US$276,000,000 ...
Source LinkVericel Corporation recently issued preliminary, unaudited guidance for the fourth quarter and full year 2025, pointing to 23% quarterly revenue and MACI sales growth and approximately US$276,000,000 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.